NCT00117156View on ClinicalTrials.gov

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

October 31, 2008

Study Completion Date

January 31, 2012

Conditions
Lymphoma, Non-HodgkinMALT Lymphoma
Interventions
DRUG

Fludarabine

DRUG

Rituximab

Trial Locations (4)

14627

University of Rochester Cancer Center, Rochester

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

Genentech, Inc.
Biogen
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

University of Rochester

OTHER

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Biogen

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER